Valor pronóstico de los niveles plasmáticos de IL 13 en pacientes con artritis reumatoidea y enfermedad pulmonar intersticial: estudio de cohorte prospectiva
Resumen
Introducción: el objetivo de este estudio fue analizar la relación entre los valores de IL13 y su pronóstico en pacientes con artritis reumatoidea (AR) y enfermedad pulmonar intersticial (EPI). Materiales y métodos: estudio de cohorte prospectiva. Se midió IL13 en suero y se dividió la cohorte en dos grupos con la mediana de IL13 como punto de corte. Se estudió el tiempo hasta una caída de la capacidad vital forzada (CVF) mayor o igual al 5% con el método de Kaplan Meier (KM) y regresión de Cox. Resultados: se incluyeron 47 pacientes. La media (DE) de tiempo de seguimiento fue de 12,7 (12,5) meses. El estimador de KM a 15 meses fue de 0,48 (IC 95% 0,13-0,76) en el grupo con valores elevados de IL13 y de 0,86 (IC 95% 0,54-0,93) en el otro grupo (p=0,037). En el análisis de Cox multivariado los valores elevados de IL13 se asociaron con una caída de la CVF mayor o igual al 5% en el seguimiento (HR 17.64 [IC 95% 1,89-164,1] p=0,012). Conclusiones: los valores elevados de IL13 se asociaron con peor evolución funcional en esta cohorte prospectiva de pacientes con AR y EPI.Citas
I. Rooney BK, Silman AJ. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1999;11:91-7. doi: 10.1097/00002281-199903000-00002.
II. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998;19:667-85. doi: 10.1016/s0272-5231(05)70109-x.
III. Zou Y-Q, Li Y-S, Ding X-N, Ying Z-H. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int 2012;32:669-73. doi: 10.1007/s00296-010-1665-1.
IV. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013;92:92-7. doi: 10.1097/MD.0b013e318289ce01.
V. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernández-Pérez ER, Solomon J, et al. Rheumatoid arthritis. Interstitial lung disease associated mortality. Am J Respir Crit Care Med 2011;183:372-8. doi: 10.1164/rccm.201004-0622OC.
VI. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis. A population-based study. Arthritis Rheum 2010;62:1583-91. doi: 10.1002/acr.21986.
VII. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Uden JH Van, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322-8. doi: 10.1183/09031936.00092309.
VIII. Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2015;67:28-38. doi: 10.1007/s11926-017-0701-5.
IX. Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 2015;191:1403-12. doi: 10.1164/rccm.201411-1950OC.
X. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. J Immunol 2004;173:4020-9. doi: 10.4049/jimmunol.173.6.4020.
XI. Sivakumar P, Ntolios P, Jenkins G, Laurent G. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 2012;18(5):462-9. doi: 10.1097/MCP.0b013e328356800f.
XII. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis: an integral model. Am J Respir Crit Care Med 2014;189:1161-72. doi: 10.1164/rccm.201312-2221PP.
XIII. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 2004;4:583-94. doi: 10.1038/nri1412.
XIV. Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: Shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin 2015;67:280-6.
XV. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med2011;365:2205-19. doi: 10.1056/NEJMra1004965.
XVI. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81. doi: 10.1002/art.27584.
XVII. Raghu G, Collard HR, Egan JJ, Martínez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. doi: 10.1164/rccm.2009-040GL.
XVIII. Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54. doi: 10.1164/rccm.200706-877OC.
XIX. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38. doi: 10.1183/09031936.05.00034805.
XX. MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-35. doi: 10.1183/09031936.05.00034905.
XXI. Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis2009;68(6):954-60. doi: 10.1136/ard.2007.084459.
XXII. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Directrices para comunicación de estudios observacionales. Gac Sanit 2008;22:144-50. doi: 10.1157/13119325.
XXIII. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006;116:3183-94. doi: 10.1172/JCI28756.
XXIV. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619-33. doi: 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V.
XXV. Paulin F, Mercado JF, Fernández ME, Caro FM, Alberti ML, Fassola LA. Correlation between lung and joint involvement in patients with rheumatoid arthritis and interstitial lung disease: A cross-sectional study. Rev Investig Clin 2018;70:76-81. doi: 10.24875/RIC.18002474.
XXVI. Chun-Geun Lee, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med. 2001;194:809-21. doi: 10.1084/jem.194.6.809.
XXVII. Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ. Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells. Br J Pharmacol. 2016;173):484-96. doi: 10.1111/bph.13371.
XXVIII. Ferreira R de CDS, Montenegro SML, Domingues ALC, Bandeira AP, Silveira CADM, Leite LAC, et al. TGF beta and IL13 in schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups. BMC Infect Dis. 2014;14:1-7. doi.org/10.1186/1471-2334-14-28229.
XXIX. Nakamura Y, Suzuki R, Mizuno T, Abe K, Chiba S, Horii Y, et al. Therapeutic implication of genetic variants of IL13 and STAT4 in airway remodelling with bronchial asthma. Clin Exp Allergy. 2016;46:1152-61. doi: 10.1111/cea.12710.
XXX. Wijsenbeek MS, Kool M, Cottin V. Targeting interleukin-13 in idiopathic pulmonary fibrosis: From promising path to dead end. Eur Respir J 2018;52(6). doi:org/10.1183/13993003.02111-2018.
XXXI. Hussein MS, El-Barbary AM, Nada DW, Gaber RA, Elkolaly RM, Aboelhawa MA. Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: Rheumatoid arthritis–associated interstitial lung disease. Int J Rheum Dis 2021;24:591- 598. doi: 10.1111/1756-185X.14084.
XXXII. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018 May;78:863-871. doi:10.1016/j.jaad.2018.01.017.
XXXIII. Seyfizadeh N, Seyfizadeh N, Gharibi T, Babaloo Z. Interleukin-13 as an important cytokine: A review on its roles in some human diseases. Acta Microbiol Immunol Hung. 2015;62(4):341-78. doi: 10.1556/030.62.2015.4.2.
XXXIV. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs 2017;77:1987-2001. doi: 10.1007/s40265-017-0835-9.
XXXV. Al-Salama ZT, Scott LJ. Baricitinib: a review in rheumatoid arthritis. Drugs 2018;78:761-72. doi.org/10.1007/s40265-018-0908-4.
XXXVI. Citera G, Mysler E, Madariaga H, Cardiel MH, Castañeda O, Richette P, et al. Low interstitial lung disease event rate in patients with rheumatoid arthritis: pooled post hoc analysis of data from the tofacitinib clinical development program. Arthritis Rheumatol 2017;42:23-6.
Derechos de autor 2022 A nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
